A Win for Trabectedin in High-Grade Myxoid Liposarcoma?
Neoadjuvant trabectedin (Yondelis) for high-grade myxoid liposarcoma (HG-MLPS) demonstrated noninferiority to the long-time standard of anthracycline-ifosfamide (AI), according to new data from a previously completed trial. Standard therapy was associated with twice as many recurrences as compared with trabectedin, translating into a 40% reduction in the hazard for disease-free survival (DFS) in favor of trabectedin. […]
Linezolid ‘Not Recommended’ to Treat Early Syphilis
Linezolid failed to meet noninferiority criteria when compared with standard benzathine penicillin G (BPG) in the treatment of early syphilis, according to findings of the randomized, controlled Trep-AB Study of cisgender men. Only 70% of trial participants with early syphilis who were treated with linezolid were cured, compared with 100% of participants treated with penicillin, […]
Favorable Long-Term Results With Ranibizumab Implant for Neovascular AMD
The ranibizumab port delivery system (PDS; Susvimo) with 6-month refill maintained noninferiority to monthly intravitreal injections for neovascular age-related macular degeneration (nAMD) out to 2 years, according to updated results from a randomized trial. Three assessments of best corrected visual acuity (BCVA) during years 1 to 2 showed differences ranging from -0.2 to +0.4 ETDRS […]
Dexamethasone or Surgery for Chronic Subdural Hematoma?
Dexamethasone treatment failed to demonstrate noninferiority to surgery for chronic subdural hematoma and was associated with more complications and a greater risk of later surgery, according to results of a randomized study terminated early due to safety and outcome concerns. In the DECSA trial, the odds ratio of a better functional outcome score with dexamethasone […]
Another Bioresorbable Stent Hits a Snag
A novel bioresorbable stent failed to meet the threshold for noninferiority compared with durable devices in the OPTIMIZE trial, and researchers suggested rising troponin use may have played a role. The Svelte stent, designed to facilitate direct stenting and transradial access in percutaneous coronary intervention (PCI), did not differ significantly from metallic everolimus-eluting stents with […]